The multicenter phase 1/2 trial will be conducted across the U.S. over the next five years and will be the first prospective human study to test a treatment specifically aimed at the condition. 

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics, highlighting advances in the development of next-generation treatment modalities and the technologies enabling them. “Next Generation Cancer Therapeutics” is scheduled for Oct. 6-8, 2026, on the UT MD Anderson campus. 

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report. Dana-Farber/Boston Children’s has been recognized as one of the top three pediatric cancer centers in the country each year since the ranking’s inception in 2007, earning more #1 rankings than any other program.

Cardiovascular disease has replaced cancer as the leading cause of death among Hispanic adults in the U.S., according to a new scientific statement from the American Heart Association.

An elevated PSA level in the blood may indicate prostate cancer, but does not yet allow for a definitive diagnosis. Where there is a corresponding suspicion, a tissue sample is therefore usually taken from the prostate. A study by the Medical University of Vienna now shows that a specialised form of imaging – known as PSMA-PET/CT – could provide important additional information even before such a biopsy is carried out. In an analysis of 194 patients, the method detected 91 per cent of clinically relevant prostate cancers. The findings of the research team, led by Marcus Hacker, Head of the Division of Nuclear Medicine at the Department of Biomedical Imaging and Image-guided Therapy, were published in the inaugural issue of the new journal The Lancet Medical Imaging & Theranostics.